Milestone Pharmaceuticals Inc.

Contributing Author

Recent Articles by Milestone Pharmaceuticals Inc.

Sep-24	Milestone Pharmaceuticals Enrolls First Canadian Study Participant in ReVeRA-301 Phase 3 Pivotal Trial Evaluating Etripamil Nasal Spray for AFib-RVR MIST -7.78% GlobeNewswire
Sep-03	Milestone Pharmaceuticals Announces NMPA Approval of Etripamil Nasal Spray for PSVT in China, Marking First Regulatory Approval of Etripamil Outside of the United States MIST GlobeNewswire
Sep-02	Milestone Pharmaceuticals to Present at Upcoming Investor Conferences MIST GlobeNewswire
Aug-27	Milestone Pharmaceuticals Announces Data Presented at ESC Congress 2026 on the Impact of Paroxysmal Supraventricular Tachycardia (PSVT) on Patients' Daily Lives and Quality of Life Between Episodes MIST GlobeNewswire
Aug-21	Milestone Pharmaceuticals Initiates Pivotal Phase 3 Trial of Etripamil Nasal Spray for Self-Administered Treatment of Atrial Fibrillation with Rapid Ventricular Rate (AFib-RVR) MIST GlobeNewswire
Aug-12	Milestone Pharmaceuticals Announces Second Quarter 2026 Financial Results and Provides Corporate Update MIST -11.42% GlobeNewswire
Aug-04	Milestone Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 12, 2026 MIST GlobeNewswire
Jul-02	Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MIST GlobeNewswire
May-14	Milestone Pharmaceuticals to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ MIST -5.23% GlobeNewswire
May-13	Milestone Pharmaceuticals Announces First Quarter 2026 Financial Results and Provides Corporate Update MIST -9.47% GlobeNewswire
May-06	Milestone Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 13, 2026 MIST GlobeNewswire
Apr-10	Milestone Pharmaceuticals Announces RESET-PSVT Registry to Generate Real-World Evidence on CARDAMYST (etripamil) Nasal Spray in Patients With PSVT MIST GlobeNewswire
Apr-07	Milestone Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference MIST +5.92% GlobeNewswire
Apr-02	Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MIST +5.34% GlobeNewswire
Mar-31	Milestone Pharmaceuticals Announces that CARDAMYST (etripamil) Nasal Spray is Available on Express Scripts Commercial National Formularies MIST +17.82% GlobeNewswire
Mar-20	Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Update on the Commercial Launch of CARDAMYST (etripamil) Nasal Spray for the Treatment of PSVT MIST -20.00% GlobeNewswire
Mar-16	Milestone Pharmaceuticals to Present Data on CARDAMYST (etripamil) Nasal Spray at the 2026 American College of Cardiology Annual Scientific Session MIST GlobeNewswire
Mar-12	Milestone Pharmaceuticals to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 20, 2026 MIST GlobeNewswire
Feb-26	Milestone Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference MIST GlobeNewswire
Feb-10	Milestone Pharmaceuticals Appoints David Sandoval as General Counsel and Chief Compliance Officer MIST GlobeNewswire
Feb-03	Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MIST GlobeNewswire
Jan-26	Milestone Pharmaceuticals Announces U.S. Availability of CARDAMYST (etripamil) Nasal Spray, the First and Only FDA-Approved Self-Administered Treatment for Adults with Paroxysmal Supraventricular Tachycardia (PSVT) MIST GlobeNewswire
Jan-06	Milestone Pharmaceuticals Announces Acceptance of Marketing Authorization Application for Etripamil Nasal Spray in PSVT by the European Medicines Agency MIST GlobeNewswire
Dec-12	Milestone Receives FDA Approval of CARDAMYST (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT) MIST GlobeNewswire
Dec-02	Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MIST GlobeNewswire
Nov-12	Milestone Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Regulatory and Corporate Update MIST GlobeNewswire
Nov-04	Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MIST GlobeNewswire
Nov-03	Milestone Pharmaceuticals to Present New Analysis from Investigational Etripamil Nasal Spray Clinical Trials for PSVT at the American Heart Association Scientific Sessions 2025 MIST GlobeNewswire
Oct-09	Milestone Pharmaceuticals to Present Data on Etripamil at the American Heart Association Scientific Sessions 2025 MIST GlobeNewswire
Aug-19	Milestone Pharmaceuticals to Present at Upcoming Conferences MIST GlobeNewswire
Aug-12	Milestone Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Regulatory and Corporate Update MIST +7.10% GlobeNewswire
Jul-11	Milestone Pharmaceuticals Announces Pricing of $52.5 Million Public Offering of Common Shares, Pre-Funded Warrants, Series A Common Warrants and Series B Common Warrants MIST -39.06% GlobeNewswire
Jul-11	Milestone Pharmaceuticals Announces Proposed Public Offering MIST -39.06% GlobeNewswire
Jul-11	Milestone Pharmaceuticals Announces FDA Acceptance of the Company's Response to the CRL for CARDAMYST (etripamil) Nasal Spray MIST -39.06% GlobeNewswire
Jun-16	Milestone Pharmaceuticals Submits Response to the FDA's CRL for CARDAMYST (etripamil) Nasal Spray for PSVT Following Type A Meeting MIST GlobeNewswire
May-28	Milestone Pharmaceuticals to Present at the Jefferies Global Healthcare Conference MIST +7.04% GlobeNewswire
May-14	Milestone Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Regulatory and Corporate Update MIST GlobeNewswire

Milestone Pharmaceuticals Inc.

Recent Articles by Milestone Pharmaceuticals Inc.

Upgrade your Finviz experience